Identification of a Non-Stop Mutation in PAX6 Causing a Unique Presentation of Aniridia in an Iranian Family Trial

  • Mehran Zarei-Ghanavati Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Reza Ghaffari Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Hoda Abedkhojasteh Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Kasra Raoufian Department of General Surgery, Sina Hospital, Mashhad, Iran.
  • Reza Raoofian Mail Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran.
  • Masoumehe Mohebbi Farabi Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Mansour Heidari Department of Molecular Biology and Genetics, Islamic Azad University, Bushehr Branch, Bushehr, Iran. AND Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Keywords:
Eye disorder, PAX6, Non-stop mutation

Abstract

Non-syndromic aniridia (iris hypoplasia) as an autosomal dominant eye disorder results from the chromosomal abnormalities and mutations within the paired box gene 6 (PAX6). The aim of this study was to investigate on the clinical and the underlying genetic alteration in PAX6 gene in a large pedigree with five generations of Iranian family with an autosomal dominant aniridia. Here, we reported unique clinical features in terms of presenting nystagmus, ptosis, minimal iris abnormality, foveal hypoplasia and late-onset clinical limbal stem cell deficiency. Genomic DNA was extracted from the affected members and polymerase chain reaction (PCR) was conducted using specific primers to amplify coding sequence of PAX6. Then, PCR products were subjected to bidirectional dye terminator sequencing. A heterozygous transversion mutation A→T (c.1268A>T, p.*423Lext*15) in exon 13 of PAX6 was identified in all affected individuals, but not in the healthy members. This is the first report of non-stop mutation in PAX6 gene in an Iranian family accompanied with an isolated form of unusual congenital aniridia running within this family.

References

Edén U, Iggman D, Riise R, Tornqvist K: Epidemiology of aniridia in sweden and norway. Acta Ophthalmologica 2008;86:727-729.

Glaser T, Walton D, Maas R: Genomic structure, evolutionary conservation and aniridia mutations in the human pax6 gene. Nat Genet 1992;2:232-239.

Churchill A, Booth A: Genetics of aniridia and anterior segment dysgenesis. The British Journal of Ophthalmology 1996;80:669-673.

Hingorani M, Hanson I, van Heyningen V: Aniridia. Eur J Hum Genet 2012;20:1011-1017.

Brown A, McKie M, Van Heyningen V, Prosser J: The human pax6 mutation database. Nucleic acids research 1998;26:259-264.

Ansari M, Rainger J, Hanson IM, Williamson KA, Sharkey F, Harewood L, Sandilands A, Clayton-Smith J, Dollfus H, Bitoun P: Genetic analysis of ‘pax6-negative’individuals with aniridia or gillespie syndrome. PLOS ONE 2016;11:e0153757.

Chi N, Epstein JA: Getting your pax straight: Pax proteins in development and disease. Trends in Genetics 2002;18:41-47.

Georgala PA, Carr CB, Price DJ: The role of pax6 in forebrain development. Developmental Neurobiology 2011;71:690-709.

Georgala PA, Manuel M, Price DJ: The generation of superficial cortical layers is regulated by levels of the transcription factor pax6. Cerebral Cortex 2011;21:81-94.

Prosser J, van Heyningen V: Pax6 mutations reviewed. Human Mutation 1998;11:93-108.

Villarroel CE, Villanueva-Mendoza C, Orozco L, Alcántara-Ortigoza MA, Jiménez DF, Ordaz JC, González-del Angel A: Molecular analysis of the pax6 gene in mexican patients with congenital aniridia: Report of four novel mutations. Molecular Vision 2008;14:1650-1658.

Kokotas H, Petersen MB: Clinical and molecular aspects of aniridia. Clinical Genetics 2010;77:409-420.

Skeens HM, Brooks BP, Holland EJ: Congenital aniridia variant: Minimally abnormal irides with severe limbal stem cell deficiency. Ophthalmology 2011;118:1260-1264.

Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NST, Cooper DN: The human gene mutation database: 2008 update. Genome Medicine 2009;1:13-13.

Akimitsu N, Tanaka J, Pelletier J: Translation of nonstop mRNAis repressed post-initiation in mammalian cells. The EMBO Journal 2007;26:2327-2338.

Isken O, Maquat LE: Quality control of eukaryotic mrna: Safeguarding cells from abnormal mrna function. Genes & Development 2007;21:1833-3856.

Wagner E, Lykke-Andersen J: Mrna surveillance: The perfect persist. Journal of Cell Science 2002;115:3033-3038.

Vasudevan S, Peltz SW, Wilusz CJ: Non-stop decay—a new mRNA surveillance pathway. BioEssays 2002;24:785-788.

Hamby SE, Thomas NST, Cooper DN, Chuzhanova N: A meta-analysis of single base-pair substitutions in translational termination codons ('nonstop' mutations) that cause human inherited disease. Human Genomics 2011;5:241-264.

Williamson K, Sharkey F, Harewood L: Genetic analysis of ‘pax6-negative’individuals with aniridia or gillespie syndrome. PLOS ONE 2016;1:15.

Wang X, Shan X, Gregory-Evans CY: A mouse model of aniridia reveals the in vivo downstream targets of pax6 driving iris and ciliary body development in the eye. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 2017;1863:60-67.

Published
2018-02-17
How to Cite
1.
Zarei-Ghanavati M, Ghaffari R, Abedkhojasteh H, Raoufian K, Raoofian R, Mohebbi M, Heidari M. Identification of a Non-Stop Mutation in PAX6 Causing a Unique Presentation of Aniridia in an Iranian Family Trial. Acta Med Iran. 56(2):84-89.
Section
Articles